ArticleActa pharmaceutica Sinica. B2022

YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer.

Fangfang Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.